// App-Quantinova.ai

977 : Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)

Researchers

Presenter

  • Jason S Knight

Principal Investigators

  • Winn Walter Chatham

  • Christine Henning

  • Julia H N Harris

  • Andre Van Maurik

  • Roger A Levy

  • David Pisetsky

Medical Centers

  • University of Michigan Rheumatology, Ann Arbor, MI

  • University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL

  • GlaxoSmithKline, Global Medical Affairs, Durham, NC

  • GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom

  • GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom

  • GlaxoSmithKline, Global Medical Affairs, Collegeville, PA

  • Duke University Medical Center, Durham, NC

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Belimumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved